Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a devastating, rapidly progressive, and often fatal complication of stem cell transplantation. For years, clinicians have been forced to rely on off-label therapies with limited success. However, the therapeutic landscape shifted dramatically with the recent introduction of Narsoplimab (development code: OMS721, approved under the brand name YARTEMLEA®).

Approved by the US FDA in December 2025, Narsoplimab made history as the first and only targeted treatment specifically indicated for TA-TMA. By isolating and neutralizing a specific arm of the complement system, it offers researchers a masterclass in precision immunology.

Here is everything researchers need to know about the structural profile, mechanism of action (MoA), manufacturer details, and the latest clinical data for Narsoplimab.

Narsoplimab is a highly specialized biologic engineered to intervene in the complement cascade without leaving immunocompromised transplant patients entirely defenseless against infections.

• The Molecule: Narsoplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody.

• The Target: It selectively binds to and inhibits MASP-2 (mannan-binding lectin-associated serine protease-2).

• Developer: The drug was discovered and developed by Omeros Corporation (who recently entered a major $2.1 billion licensing agreement with Novo Nordisk for complement-mediated disease targets).

• Administration: It is administered as an intravenous (IV) infusion, typically dosed once or twice weekly depending on the specific clinical protocol and patient weight.

The human complement system is activated via three distinct routes: the classical, alternative, and lectin pathways. Narsoplimab’s efficacy and safety stem from its ability to exclusively shut down the lectin pathway:

1. The Root Cause of TA-TMA: The heavy conditioning regimens, immunosuppressants, and infections associated with stem cell transplants cause severe endothelial injury. This tissue damage directly triggers the overactivation of the lectin pathway of the complement system.

2. The Effector Enzyme: MASP-2 is the central effector enzyme of this lectin pathway. When activated, it cleaves downstream complement proteins (C4 and C2), driving a runaway cascade that results in severe microvascular thrombosis, hemolytic anemia, and multi-organ failure.

3. Targeted Inhibition: Narsoplimab binds directly to MASP-2 with nanomolar affinity. By inhibiting MASP-2, the drug acts as a precise circuit breaker, halting the lectin pathway at its earliest stage and preventing the downstream inflammatory and thrombotic damage.

4. Pathway Selectivity (The Key Differentiator): Unlike broad-spectrum complement inhibitors (such as C5 inhibitors like Eculizumab), Narsoplimab only blocks the lectin pathway. It leaves the classical and alternative complement pathways entirely intact. This is critical for post-transplant patients, as it preserves their adaptive immune response and ability to clear life-threatening bacterial and viral infections.

The FDA approval of Narsoplimab was supported by a robust data package, including a pivotal Phase 2/3 single-arm, open-label trial (N=28) and a massive Expanded Access Program (EAP) encompassing over 220 patients, including critically ill pediatric populations.

Because TA-TMA is an ultra-rare and historically fatal condition, efficacy was evaluated using a rigorous composite definition of Complete Response (CR), which required simultaneous improvements in platelet counts, lactate dehydrogenase (LDH) levels, and organ function/transfusion independence.

Narsoplimab was well-tolerated. The most common adverse events—such as neutropenia, fever, and gastrointestinal issues—were typical of the highly complex post-HSCT patient population. Crucially, the selective nature of the MASP-2 inhibition meant there were no new safety signals regarding opportunistic infections that typically plague broader complement blockade.

With its landmark FDA approval in December 2025 (brand name YARTEMLEA®) for adults and children 2 years and older, Narsoplimab became the standard of care for TA-TMA overnight. A marketing authorization application is currently under review by the European Medicines Agency (EMA), with a decision expected in mid-2026.

However, the lectin pathway plays a role in numerous other diseases. Omeros and Novo Nordisk are aggressively exploring Narsoplimab's potential in other complement-mediated disorders, with late-stage clinical programs already well underway for Immunoglobulin A Nephropathy (IgAN) and Atypical Hemolytic Uremic Syndrome (aHUS).

Investigating the lectin complement pathway, MASP-2 inhibition, or novel approaches to endothelial injury syndromes? ichorbio offers a highly purified, research-grade Narsoplimab biosimilar available through our exclusive product-on-demand service. Manufactured to strict specifications for low endotoxin and high structural fidelity, this molecule is engineered specifically for your complex in vitro and in vivo preclinical assays.

Note: As an on-demand custom build, please allow a 4-week lead time for synthesis and purification.